MedDataX Logo

Diagnostic Utility of Pleural Fluid MAGE Assay in Patients With Pleural Effusion From Primary Lung Cancer

NCT ID: NCT01179685

Last Updated: 2011-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Melanoma antigen (MAGE) gene is known to be expressed in tumor cells, testis and placenta. The purpose of this prospective study was to investigate the sensitivity, specificity and accuracy of pleural fluid MAGE gene expression, tumor marker and cytology in the diagnosis of malignant pleural effusion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Longitudinal Follow up of Patients With Pleural Effusion

NCT04670562

Pleural Effusion, Malignant Prognosis
RECRUITING

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795

Non Small-cell Lung Cancer
COMPLETED

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

NCT00897143

Lung Cancer Metastatic Cancer
WITHDRAWN

Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood

NCT05587114

Lung Cancer Diagnosis
RECRUITING

Immunomagnetic Detection of Cancer Cells in Pleural Effusion in Lung Cancer Patients as Additional Staging and Prognostic Tool

NCT02172027

Lung Cancer
WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unilatral Pleural Effusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pleural fluid tapping

Minimally invasive technique to detect malignant pleural effusion

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* unilateral pleural effusion on chest radiography

Exclusion Criteria

* body temperature \> 38.3ºC and peripheral blood leukocytosis (\>12,000/μl)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Samsung Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Samsung Medical Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sang-Won Um, MD

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Samsung Medical Center

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-08-043

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
NCT05693727 NOT_YET_RECRUITING
Prognostic Factors on Malignant Pleural Effusion
NCT03276715 COMPLETED
Analysis of Metabonomics for Pleural Effusion
NCT05906823 COMPLETED
Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
NCT04887545 UNKNOWN
Identification of a Plasma Proteomic Signature for Lung Cancer
NCT01752101 COMPLETED
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
NCT00568282 COMPLETED
Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion
NCT00313066 UNKNOWN
The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients
NCT02714335 COMPLETED
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
NCT01837511 COMPLETED
CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy
NCT04704960 UNKNOWN
The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring
NCT02437760 UNKNOWN
Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
NCT07012759 NOT_YET_RECRUITING
A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer
NCT04254497 COMPLETED
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
NCT07331701 NOT_YET_RECRUITING
A Multi-Center Trial of the ProLung Test™
NCT01566682 COMPLETED
PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection
NCT05874648 UNKNOWN
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment
NCT00752076 UNKNOWN NA
Intraoperative Imaging of Pulmonary Nodules by OTL38
NCT02602119 COMPLETED PHASE1
Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer
NCT07262671 ACTIVE_NOT_RECRUITING
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion
NCT01256801 COMPLETED
Cancer Panel From Blood of Lung Cancer Patients
NCT03235765 UNKNOWN
A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine
NCT02597738 ACTIVE_NOT_RECRUITING NA
A Prospective, Observational Trial on the Diagnostic and Prognostic of LM
NCT02607605 UNKNOWN
The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction
NCT00690261 UNKNOWN
Liquid Biopsy in Lung Cancer
NCT03479099 COMPLETED